0001193125-21-310430 | 6-K/A | XBRL Viewer

Print Document View Excel Document

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2021
Document Information [Line Items]
Document Type	6-K/A
Amendment Flag	true
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	Immatics N.V.
Entity Central Index Key	0001809196
Current Fiscal Year End Date	--12-31
Entity File Number	001-39363
Entity Address, Address Line One	Paul-Ehrlich-Straße 15
Entity Address, City or Town	Tübingen
Amendment Description	This Amendment No.1 to Form 20-F (this “Amendment” or “Form 20-F/A”) amends the Immatics N.V. (“Immatics” or the “Company”) Annual Report on Form 20-F for the year ended December 31, 2020 originally filed with Securities and Exchange Commission (“SEC”) on March 30, 2021 (the “Original Filing”). This Amendment restates the Company’s previously issued consolidated financial statements as of and for the year ended December 31, 2020.

Condensed Consolidated Statement of Financial Position of Immatics N.V. - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	€ 160,093	€ 207,530
Other financial assets	32,712	24,448
Accounts receivable	718	1,250
Other current assets	4,815	5,763
Total current assets	198,338	238,991
Non-current assets
Property, plant and equipment	8,747	7,868
Intangible assets	1,262	914
Right-of-use assets	7,313	6,149
Other non-current assets	845	724
Total non-current assets	18,167	15,655
Total assets	216,505	254,646
Current liabilities
Provisions	1,960	51
Accounts payable	9,407	10,052
Deferred revenue	57,998	46,600
Other financial liabilities	20,805	16,869
Lease liabilities	2,321	1,881
Other current liabilities	1,442	2,025
Total current liabilities	93,933	77,478
Non-current liabilities
Deferred revenue	62,201	85,475
Lease liabilities	4,736	4,306
Total non-current liabilities	66,937	89,781
Shareholders' equity
Share capital	629	629
Share premium	554,965	538,695
Accumulated deficit	(493,824)	(444,478)
Other reserves	(6,135)	(7,459)
Total shareholders' equity	55,635	87,387
Total liabilities and shareholders' equity	€ 216,505	€ 254,646

Condensed Consolidated Statement of Loss of Immatics N.V. - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Profit or loss [abstract]
Revenue from collaboration agreements	€ 5,189	€ 6,896	€ 12,592	€ 13,936
Research and development expenses	(20,340)	(16,505)	(43,389)	(28,751)
General and administrative expenses	(8,271)	(10,076)	(16,702)	(16,264)
Other income	26	86	265	200
Operating result	(23,396)	(19,599)	(47,234)	(30,879)
Financial income	213	437	3,101	1,083
Financial expenses	(629)	(2,164)	(1,277)	(110)
Change in fair value of warrant liabilities	(2,722)		(3,936)
Financial result	(3,138)	(1,727)	(2,112)	973
Loss before taxes	(26,534)	(21,326)	(49,346)	(29,906)
Taxes on income		0		0
Net loss	(26,534)	(21,326)	(49,346)	(29,906)
Attributable to:
Equity holders of the parent	(26,534)	(21,043)	(49,346)	(29,349)
Non-controlling interest		(283)		(557)
Net loss	€ (26,534)	€ (21,326)	€ (49,346)	€ (29,906)
Net loss per share—basic and diluted	€ (0.42)	€ (0.64)	€ (0.78)	€ (0.89)
Weighted average shares outstanding—basic and diluted	62,909,095	33,093,838	62,908,945	33,093,838

Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V. - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of comprehensive income [abstract]
Net Loss	€ (26,534)	€ (21,326)	€ (49,346)	€ (29,906)
Items that may be reclassified subsequently to profit or loss, net of tax
Currency translation differences from foreign operations	(1,401)	791	1,324	99
Total comprehensive loss for the period	(27,935)	(20,535)	(48,022)	(29,807)
Attributable to:
Equity holders of the parent	(27,935)	(20,252)	(48,022)	(29,250)
Non-controlling interest	(27,935)	(283)	0	(557)
Total comprehensive loss for the period	€ (27,935)	€ (20,535)	€ (48,022)	€ (29,807)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2020-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2020-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2020-01-01

+ Details

Condensed Consolidated Statement of Cash Flows of Immatics N.V. - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Loss before taxation	€ (49,346)	€ (29,906)
Adjustments for:
Interest income	(87)	(755)
Depreciation and amortization	2,264	2,288
Interest expense	140	110
Equity settled share-based payment	16,270	6,928
MD Anderson compensation expense		45
Increase in other liabilities resulting from share appreciation rights		7,773
Cash-out related to share-based compensation previously classified as equity-settled		(4,322)
Net foreign exchange differences	236	1
Change in fair value of warrant liabilities	3,936
Changes in working capital
Decrease in accounts receivable	532	530
Decrease/(increase) in other assets	902	(1,106)
Increase in accounts payable and other current liabilities	(11,363)	(9,724)
Interest received	54	510
Interest paid	(140)	(110)
Net cash used in operating activities	(36,602)	(27,738)
Cash flows from investing activities
Payments for property, plant and equipment	(1,912)	(4,514)
Cash paid for investments classified in Other financial assets	(53,782)	(32,859)
Cash received from maturity of investments classified in Other financial assets	45,770	48,881
Payments for intangible assets	(390)	(36)
Proceeds from disposal of property, plant and equipment	8	0
Net cash (used in)/provided by investing activities	(10,306)	11,472
Cash flows from financing activities
Payments for leases	(1,348)	(1,168)
Net cash used in financing activities	(1,348)	(1,168)
Net decrease in cash and cash equivalents	(48,256)	(17,434)
Cash and cash equivalents at beginning of period	207,530	103,353
Effects of exchange rate changes on cash and cash equivalents	819	137
Cash and cash equivalents at end of period	€ 160,093	€ 86,056

Condensed Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V. - EUR (€) € in Thousands	Total	Share capital [member]	Share premium [member]	Accumulated deficit [member]	Other reserves [member]	Total equity (deficit) attributable to shareholders of the parent [member]	Non-controlling interests [member]
Beginning Balance at Dec. 31, 2019	€ (40,835)	€ 1,164	€ 190,945	€ (233,194)	€ (770)	€ (41,855)	€ 1,020
Other comprehensive income (loss)	99				99	99
Net Loss	(29,906)			(29,349)		(29,349)	(557)
Comprehensive income/(loss) for the year	(29,807)			(29,349)	99	(29,250)	(557)
Equity-settled share-based compensation	6,928		6,928			6,928
Cash-out related to share-based compensation previously classified as equity-settled	(4,322)		(4,322)			(4,322)
MD Anderson milestone compensation expense	45						45
Ending Balance at Jun. 30, 2020	(67,991)	1,164	193,551	(262,543)	(671)	(68,499)	€ 508
Beginning Balance at Dec. 31, 2020	87,387	629	538,695	(444,478)	(7,459)	87,387
Other comprehensive income (loss)	1,324				1,324	1,324
Net Loss	(49,346)			(49,346)		(49,346)
Comprehensive income/(loss) for the year	(48,022)			(49,346)	1,324	(48,022)
Equity-settled share-based compensation	16,270		16,270			16,270
Ending Balance at Jun. 30, 2021	€ 55,635	€ 629	€ 554,965	€ (493,824)	€ (6,135)	€ 55,635

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

Group information

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Group information

1. Group information

Immatics N.V, together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (“Immatics” or “the Group”) is a biotechnology group that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics N.V., a Dutch public limited liability company, was converted on July 1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc. became subsidiaries of Immatics N.V. as part of the ARYA Merger on July 1, 2020. Immatics N.V is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 Tübingen, Germany. Prior to July 1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Therefore, the comparable financial results for the three and six months ended June 30, 2020, represent consolidated financial results of Immatics Biotechnologies GmbH.

These interim condensed consolidated financial statements of the Group for the three and six months ended June 30, 2021, were authorized for issue

by the Audit Committee of Immatics

N.V. on August 5, 2021

except for the impact of the matter discussed in Note 3.2

Restatement of Unaudited Condensed Consolidated Financial Statements to correct the presentation of the warrants which was approved by the Audit Committee of Immatics N.V. on October 26, 2021.

Significant events and changes in the current reporting period

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Significant events and changes in the current reporting period

2. Significant events and changes in the current reporting period

The Group was affected by the following events or transactions during the three and six months ended June 30, 2021.

COVID-19

In December 2019, a novel strain of coronavirus

(“COVID-19”)

emerged in Wuhan, China. On January 30, 2020, the World Health Organization declared the outbreak a pandemic and a global emergency. In response, many countries and businesses still institute travel restrictions, quarantines, and office closures. The extent of the pandemic and governmental responses may impact our ability to obtain raw materials and equipment used for research and development, obtain sufficient additional funds to finance our operations, and conduct clinical trials, any of which could materially and adversely affect our business.

Management continues to monitor the situation and enacted significant measures to protect the Group’s supply chain, employees, and the execution of clinical trials. To date, the pandemic has resulted in a slowdown in activities related to the Group’s laboratory operations and at some of its suppliers. The ongoing spread of

COVID-19

may also negatively impact the Group’s ability to conduct clinical trials, including potential delays and restrictions on the Group’s ability to recruit and retain patients, and the availability of principal investigators and healthcare employees.

COVID-19

could also affect the operations of contract research organizations, which may also result in delays or disruptions in the supply of product candidates. Immatics continues to expand its clinical programs with additional clinical trial sites opening in the U.S. and in Europe. Given the ongoing vaccination programs both in the U.S. and in Europe we currently do not expect significant negative impacts on the Group’s activities in the future. However,

COVID-19

also showed the ability of mutation with potential mutants in the future limiting the impact of the vaccines. This could again lead to further negative impacts.

Significant accounting policies

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Significant accounting policies

3. Significant accounting policies

3.1 Basis of presentation

The interim condensed consolidated financial statements of the Group as of June 30, 2021 and for the three and six months ended June 30, 2021 and 2020 have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”).

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s annual financial statements for the year ended December 31, 2020, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the IASB, taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (“IFRS IC”).

The interim condensed consolidated financial statements are presented in Euros. Amounts are stated in thousands of Euros, unless otherwise indicated.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2020. The new and amended standards and interpretations applied for the first time as of January 1, 2021, as disclosed in the notes to the consolidated financial statements for the year ended December 31, 2020, had no impact on the interim condensed consolidated financial statements of the Group for the three and six months ended as of June 30, 2021.

As of June 30, 2021, Immatics holds bonds.

The bonds’

contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost.

The Group had a

non-controlling

interest, representing approximately 3.96% of the Group’s Immatics US, Inc. subsidiary as of June 30, 2020, held by MD Anderson. On July 1, 2020 and as part of the ARYA Merger, this

non-controlling

interest in Immatics US, Inc. was exchanged for ordinary shares in Immatics N.V.

3.2 Restatement of Unaudited Condensed Consolidated Financial Statements to correct the presentation of the warrants

On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission (the “SEC”) together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). The Staff Statement clarified guidance for all SPAC-related companies regarding the accounting and reporting for their warrants that could result in the warrants issued by SPACs being classified as a liability measured at fair value, with non-cash fair value adjustments recorded in the statement of operations for each reporting period. This guidance was applicable for companies that reported using U.S. GAAP.

Under IFRS, there are alternative perspectives on whether warrants issued by a SPAC that are considered in determining the IFRS 2 charge for listing services can (i) continue to be accounted for under IFRS 2 and presented in equity or (ii) should be evaluated under IAS 32 and presented as a liability and adjusted to fair value at the balance sheet date.

Given the alternative perspectives, Immatics believed there was a choice to account for the warrants under IFRS 2 as part of equity or as a liability under IAS 32 and elected to present the warrants as part of equity. However, Immatics has observed that another foreign private issuer has restated its financial statements recently following the dialogue it reported with the Staff, and changed the presentation of its warrants from equity to liability under IFRS.

Immatics previously classified its warrants as equity. The Company reviewed and discussed the accounting treatment of its warrants with its financial advisors and the audit committee of its board of directors and evaluated the applicability and potential impact of the SEC Staff’s view on the accounting for the warrants under IFRS.

Following this review and evaluation, and after consulting with management, the Company’s board of directors, upon the recommendation of the audit committee, concluded that, in light of the recent developments it should restate its financial statements to correct for the misapplication of IFRS and to account for the warrants as a liability that is adjusted to fair value

The financial statements of 2020 were restated in the Amendment No. 1 of the 20-F published on October 28, 2021.

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Financial Position as of June 30, 2021:


	As of June 30, 2021
	As previously reported			Adjustment			As restated
	(Euros in thousands)
Total Assets		216,505			—			216,505

Other financial liabilities		—			20,805			20,805

Total current liabilities		73,128			20,805			93,933

Total non-current liabilities		66,937			—			66,937

Total liabilities		140,065			20,805			160,870

Shareholders’ equity (deficit)
Share capital		629			—			629
Share premium		589,609			(34,644	)		554,965
Accumulated deficit		(507,663	)		13,839			(493,824	)
Other reserves		(6,135	)		—			(6,135	)
Total equity (deficit) attributable to shareholders of the parent		76,440			(20,805	)		55,635

Total shareholders’ equity (deficit)		76,440			(20,805	)		55,635

Total liabilities and shareholders’ equity (deficit)		216,505			—			216,505

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Loss for the three-months ended and six-months ended June 30, 2021:


	Three months ended June 30, 2021									Six months ended June 30, 2021
	As previously reported			Adjustment			As restated			As previously reported			Adjustment			As restated
	(Euros in thousands)									(Euros in thousands)
Change in fair value of warrant liabilities		—			(2,722	)		(2,722	)		—			(3,936	)		(3,936	)

Financial result		(416	)		(2,722	)		(3,138	)		1,824			(3,936	)		(2,112	)

Loss before taxes		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Taxes on income		—			—			—			—			—			—

Net loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Attributable to:
Equity holders of the parent		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Non-controlling interest		—			—			—			—			—			—

Net loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)

Net loss per share - basic and diluted		(0,38	)		(0,04	)		(0,42	)		(0,72	)		(0,06	)		(0,78	)
Weighted average shares outstanding - basic and diluted		62,909,095			—			62,909,095			62,908,945			—			62,908,945

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Comprehensive Loss for the three-months ended and six-months ended June 30, 2021:


	Three months ended June 30, 202 1									Six months ended June 30, 202 1
	As previously reported			Adjustment			As restated			As previously reported			Adjustment			As restated
	(Euros in thousands)									(Euros in thousands)
Net Loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Other comprehensive loss
Currency translation differences from foreign operations		(1,401	)		—			(1,401	)		1,324			—			1,324

Total comprehensive loss for the period		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)
Attributable to:
Equity holders of the parent		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)
Non-controlling interest		—			—			—			—			—			—

Total comprehensive loss for the period		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Cash Flows for six-months ended June 30, 2021:


	Six months ended June 30, 2021
	As previously reported			Adjustment			As restated
	(Euros in thousands)
Loss before taxation		(45,410	)		(3,936	)		(49,346	)
Adjustment to reconcile net loss to net cash used in operating activities		18,823			3,936			22,759
Net cash provided by/(used in) operating activities		(36,602	)		—			(36,602	)
Net cash provided by/(used in) investing activities		(10,306	)		—			(10,306	)
Net cash provided by/(used in) financing activities		(1,348	)		—			(1,348	)

Net decrease in cash and cash equivalents		(48,256	)		—			(48,256	)

Cash and cash equivalents at beginning of period		207,530			—			207,530

Effects of exchange rate changes on cash and cash equivalents		819			—			819

Cash and cash equivalents at end of period		160,093			—			160,093

Segment information

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Segment information

4. Segment information

The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group’s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group’s resources.

Other current assets

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Other current assets

5. Other current assets


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)
Grant receivable		726		875
Prepaid expenses		1,821		2,389
Positive market value forward contract		9		914
Value added tax receivable		1,240		798
Other assets		1,019		787

Other current assets		4,815		5,763

The Group recognizes receivables for government grants, when it is reasonably assured that the grant will be received, and all contractual conditions have been complied with. As of June 30, 2021, and December 31, 2020, no receivables were considered impaired.

Prepaid expenses include prepaid insurance expenses of €0.2 million as of June 30, 2021 and €1.0 million as of December 31, 2020. The Group accrued €0.6 million as of June 30, 2021 and €0.5 million as of December 31, 2020 of incremental cost for the successful arrangement of the Celgene Switzerland LLC (“BMS”) and Genmab A/S (“Genmab”) collaboration agreements.

Additionally, prepaid expenses include expenses for licenses and software of €0.5 million as of June 30, 2021 and €0.6 million as of December 31, 2020. The remaining amount is mainly related to prepaid maintenance expenses.

Other assets include receivables from capital gains tax of €0.4 million as of June 30, 2021 and €0.4 million as of December 31, 2020. The remaining amount is mainly related to deposit expenses.

Revenue from collaboration agreements

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Revenue from collaboration agreements

6. Revenue from collaboration agreements

The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of June 30, 2021, the Group had four strategic collaboration agreements in place. All collaboration agreements are still at

pre-clinical

stage. During the three and six months ended June 30, 2021, the Group did not enter into any new collaboration agreements.

The Group earned revenue from collaboration agreements from the following collaborators during the three and six months ended June 30, 2021 and 2020:


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
	(Euros in thousands)				(Euros in thousands)


Amgen		260		561		517		2,712
Genmab		2,105		2,501		4,341		4,515
BMS		1,297		3,241		4,590		5,664
GSK		1,527		593		3,144		1,045

Total		5,189		6,896		12,592		13,936

As of June 30, 2021, the Group has not recognized any royalty or milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of June 30, 2021, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements.

The Group expects to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenue related to the collaboration agreements consists of the following as of June 30, 2021 and December 31, 2020:


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)
Current		57,998		46,600
Non-current		62,201		85,475

Total		120,199		132,075

The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of €0.05 million and €0.08 million for the three months ended June 30, 2021 and June 30, 2020.

The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of €0.13 million and €0.15 million for the six months ended June 30, 2021 and June 30, 2020.

Financial result

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Financial result

7. Financial result

Financial income and financial expenses consist of the following:


	Three months ended June 30,						Six months ended June 30,
	2021 (Restated)			2020			2021 (Restated)			2020
	(Euros in thousands)						(Euros in thousands)


Interest income from Other financial assets		38			436			87			755
Foreign currency gains		19			1			3,014			328
Gain on other financial instruments		156			—			—			—

Financial income		213			437			3,101			1,083

Interest expenses		(140	)		(81	)		(245	)		(110	)
Foreign currency losses		(489	)		(2,083	)		(101	)		—
Losses on other financial instruments		—			—			(931	)		—

Financial expenses		(629	)		(2,164	)		(1,277	)		(110	)
Change in fair value of warrant liabilities		(2,722	)		—			(3,936	)		—

Financial result		(3,138	)		(1,727	)		(2,112	)		973

Foreign currency gains mainly consist of unrealized gains in connection with our USD holdings of both cash and cash equivalents as w

ll as short-term deposits.

The fair value of the warrants increased from €2.35

per warrant as of December 31, 2020 to €2.52 per warrant as of March 31, 2021 and from €2.52

per warrant as of March 31, 2021 to €2.89

per warrant as of June 30, 2021.

The result is a

increase

in fair value of warrant liabilities of €2.7 million for the three months ended June 30, 2021 and €3.9 million for the six months ended June 30, 2021.

Gains and losses on other financial instruments consist of losses from unrealized currency forward contracts.

Income Tax

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Income Tax

8. Income Tax

During the three and six months ended June 30, 2021 and 2020, the Group generated losses in both Germany and the U.S. During the three and six months ended June 30, 2021 and 2020, the Group’s German operations were subject to a statutory tax rate of 29.1%. In the U.S., the Group was subject to a corporate income tax rate of 21% during the three and six months ended June 30, 2021 and 2020.

As of June 30, 2021, and December 31, 2020, no deferred tax assets have been recognized in respect of these losses, due to the uncertainty of the Group’s ability to generate taxable profits in the foreseeable future. The current assessment regarding the usability of deferred tax assets may change, depending on the Group’s taxable income in future years, which could result in the recognition of deferred tax assets This may result in higher or lower deferred tax assets related to tax losses carried forward.

Due to the ARYA Merger described in Note 3 of the Group’s annual financial statements for the year ended December 31, 2020, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section 382 of the U.S. Internal Revenue Code.

Intangible assets, Property, plant and equipment and Right-of-use assets

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Intangible assets, Property, plant and equipment and Right-of-use assets

Intangible assets, Property, plant and equipment and

Right-of-use

assets

During the three months ended June 30, 2021 and June 30, 2020, the Group acquired property,

plant and equipment and intangible assets in the

amount of €.1.8 million

and €1.3 million, respectively.

During the six months ended June 30, 2021 and June 30, 2020, the Group acquired property, plant and

equipment and intangible assets in the amount of

€2.4 million and €3.0 million, respectively.

During the six months ended June 30, 2021, new leases and extensions to existing lease agreements resulted in an addition in

right-of-use

assets and corresponding lease

liability in the amount of €1.8 million,

mainly due to the commencement of a lease agreement of rental land in Tübingen, Germany, an additional office floor in Tübingen, Germany, an additional office floor in München, Germany and a laboratory asset. The future lease payments for these lease contracts are approximately €0.3 million for the remainder of year 2021,

€1.5

million within one to five years and €

0.1

million for fiscal years after 2025. The Group used its incremental borrowing rate (“IBR”) to calculate the initial lease liability.

Provisions

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Provisions

10. Provisions

Provisions consisted of the following as of June 30, 2021 and December 31, 2020:


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)

Other provision		50		51
Provision for bonuses		1,910		—

Total provisions		1,960		51

These amounts include provisions for the Group’s annual employee bonuses. These amounts are classified as a provision as of June 30, 2021, because the amount to be paid is uncertain.

Other current liabilities

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Other current liabilities

11. Other current liabilities

Other current liabilities consisted of the following as of June 30, 2021 and December 31, 2020.


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)

Payroll tax		296		1,185
Accrual for vacation		1,021		525
Accrued bonuses		—		154
Other		125		161

Total		1,442		2,025

Share-based payments

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Share-based payments

12. Share-based payments

Immatics Biotechnologies GmbH previously issued share-based awards to employees under two different plans. Under the Immatics Biotechnologies GmbH Stock Appreciation Program 2010 (the “2010 Plan”), the Company issued stock appreciation rights (“SARs”), which the Group accounted for as cash-settled awards. Under the Immatics Biotechnologies 2016 Equity Incentive Plan (“2016 Plan”), the Company issued tandem awards, which contained the possibility to function as either a SAR or a stock option.

The Group accounted for awards issued under the 2016 Plan, which were redeemable in either cash or equity shares at the Group’s discretion, as equity settled.

For the six months ended June 30, 2020, Immatics recognized €0.8 million expenses in connection with the 2010 and 2016 Plan, of which €0.7 million and €0.1 million relate to cash and equity settled awards, respectively.

Prior to the ARYA Merger, Immatics N.V. established the new equity incentive plan (“2020 Equity Plan”). As part of the ARYA Merger, all outstanding awards under the 2010 Plan and 2016 Plan were replaced by a combination of cash payments and share-based awards under the 2020 Equity Plan in Immatics N.V. Under the 2020 Plan, management and employees have been granted different types of options.

As part of the replacement, active employees and management members received stock options (“Matching Stock Options”) to acquire shares in Immatics N.V. The Matching Stock Options have an exercise price of $10.00 and vest in full on July 31, 2021. The award recipient must remain employed by Immatics or one of its affiliates through the vesting date, to receive the option. The awards have a

ten-year

contract life.

Matching Stock Options outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number
Matching Stock Options outstanding on January 1,		10.00		1,422,556
Matching Stock Options forfeited		10.00		9,254
Matching Stock Options exercised		—		—
Matching Stock Options expired		—		—
Matching Stock Options outstanding on June 30,		10.00		1,413,302
Matching Stock Options vested		10.00		38,702
Weighted average remaining contract life (years)		9.01

For any outstanding 2016 Plan and 2010 Plan awards scheduled to vest on or after January 1, 2021, employees received replacement stock options (“Converted Options”) to acquire shares in Immatics N.V. The Converted Options have comparable terms as previous awards, with revised exercise prices reflecting the reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan that gives employees the right to acquire shares in Immatics N.V., are accounted for as a modification under IFRS 2, with the incremental fair value expensed over the remaining vesting period.

The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan to acquire shares in Immatics N.V., and the fair value of the exchanged unvested SAR (both measured at the date on which the replacement award is issued).

Based on the terms of the Converted Options award agreements, the awards had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July 1, 2020.

Converted Options outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number

Converted Options outstanding on January 1,		2.58		594,844
Converted Options forfeited		1.20		16,958
Converted Options exercised		1.25		734
Converted Options expired		1.20		1,637
Converted Options outstanding on June 30,		2.47		575,515
Converted Options vested		2.49		99,211
Weighted average remaining contract life (years)		6.51

Under the 2020 Plan, Immatics also issues employee stock options with a service requirement (“Service Options”), to acquire shares of Immatics N.V. The service-based options will vest solely on a four-year time-based vesting schedule. These Service Options are granted on a recurring basis.

The Company granted Service Options on March 30, 2021, June 17, 2021 and on June 29, 2021 which were accounted for using the respective grant date fair value. Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options, with a weighted average fair value of $8.48 for Service Option granted during the six months ended June 30, 2021.


	As of March 30, 2021			As of June 17, 2021			As of June 29, 2021
Exercise price in USD	$	11.68		$	12.05		$	11.93
Underlying share price in USD	$	11.68		$	12.05		$	11.93
Volatility		85.77	%		84.67	%		84.53	%
Time period (years)		6.1			6.11			6.10
Risk free rate		1.17	%		1.10	%		1.08	%
Dividend yield		0.00	%		0.00	%		0.00	%

Service Options outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number

Service Options outstanding on January 1,		9.87		1,910,182
Service Options granted in March,		11.68		90,325
Service Options granted in June,		11.99		75,980
Service Options forfeited		10.46		109,110
Service Options exercised		—		—
Service Options expired		—		—
Service Options outstanding on June 30,		10.65		1,967,377
Service Options vested		—		—
Weighted average remaining contract life (years)		9.57

In addition, after the closing of the ARYA Merger certain executive officers and key personnel of the Group received under the 2020 Equity Plan performance-based options (“PSUs”), vesting based on both the achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. The PSUs are split into three equal tranches. The performance criteria for each of the three respective tranches requires Immatics to achieve a market capitalization of at least $1.5 billion, $2 billion and $3 billion, respectively.

A Monte-Carlo simulation model has been used to measure the fair value at grant date of the PSUs. This model incorporates the impact of the performance criteria regarding market capitalization described above in the calculation of the award’s fair value at grant date.

There were no PSUs granted during the three and six months ended June 30, 2021.

PSUs outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number

PSUs outstanding on January 1,		10.00		3,644,000
PSUs forfeited		10.00		12,000
PSUs outstanding on June 30,		10.00		3,632,000
PSUs vested		—		—
Weighted average remaining contract life (years)		9.11

The Group recognized total employee-related share-based compensation expense, during the three and six months ended June 30, 2021 and 2020 as set out below:


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
	(Euros in thousands)				(Euros in thousands)

Research and development expenses		4,676		4,843		9,574		5,284
General and administrative expenses		3,289		3,848		6,695		4,135

Total share-based compensation		7,965		8,691		16,269		9,419

The increase in share-based compensation expense for the six months ended June 30, 2021 is attributable to replacement awards issued under the 2020 Equity Plan for the outstanding awards under the 2010 Plan and 2016 Plan and the new awards issued under the 2020 Equity Plan, as described above.

Related party disclosures

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Related party disclosures

13. Related party disclosures

During the three and six months ended June 30, 2021 the Group did not enter into any new related-party transactions with its key management personnel or with related entities other than renewed service contracts for members of the Supervisory Board based on their election at the Annual General Meeting held on June 17, 2021. As part of his election, Dr. Friedrich von Bohlen und Halbach has been granted 25,000 Service Options.

Financial Instruments

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Financial Instruments

14. Financial Instruments

Set out below are the carrying amounts and fair values of the Group’s financial instruments that are carried in the interim condensed consolidated financial statements.


Euros in thousands		Carrying amount				Fair value
	IFRS 9	June 30, 2021 (Restated)		December 31, 2020		June 30, 2021 (Restated)		December 31, 2020

Financial assets
Short-term deposits*	other financial assets at amortized cost		21,037		24,448		21,037		24,448
Bonds*	other financial assets at amortized cost		11,675		—		11,666		—
Positive market value forward contract*	At fair value through profit or loss (FVTPL)		9		914		9		914
Accounts receivable	other financial assets at amortized cost		718		1,250		718		1,250
Other current/non-current assets	other financial assets at amortized cost		578		1,586		578		1,586

Total financial assets**			34,017		28,198		34,008		28,198

Financial liabilities
Accounts payable	other financial liabilities at amortized cost		9,407		10,052		9,407		10,052
Negative market value forward contracts*	At fair value through profit or loss (FVTPL)		40		—		40		—
Other current liabilities	other financial liabilities at amortized cost		1,402		2,025		1,402		2,025
Other financial liabilities	At fair value through profit or loss (FVTPL)		20,805		16,869		20,805		16,869

Total financial liabilities			31,654		28,946		31,654		28,946

*	“Short-term deposits” are classified within Other financial assets. “Bonds” are classified within Other financial assets. “Positive market value forward contract” are classified in Other current assets. “Negative market value forward contracts” are classified in Other current liabilities.

**	Financial assets, other than cash and cash equivalents.

The carrying value of financial instruments, such as cash and cash equivalents, deposits, accounts receivable and accounts payable approximate their fair value based on the short-term maturities of these instruments. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair values: All financial assets, except for derivatives, which are categorized Level 2, are categorized Level 1 and therefore are valued using quoted (unadjusted) market prices. All financial liabilities are also categorized Level 1.

The Company accounted for the warrants issued to investors with a cashless exercise mechanism as a current financial liability according to provisions of IAS 32. The Company measured the warrants at fair value by using the closing price of warrants at NASDAQ. The warrants were measured in each reporting period. Changes in the fair value were recognized in the Company’s consolidated statement of loss as financial income or expense, as appropriate. The warrants were classified as level 1.

Events occurring after the reporting period

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Events occurring after the reporting period

15. Events occurring after the reporting period

The Company evaluated subsequent events for recognition or disclosure through August 10, 2021 and did not identify material subsequent events.

Significant accounting policies (Policies)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Basis of presentation

3.1 Basis of presentation

The interim condensed consolidated financial statements are presented in Euros. Amounts are stated in thousands of Euros, unless otherwise indicated.

As of June 30, 2021, Immatics holds bonds.

The bonds’

The Group had a

non-controlling

interest, representing approximately 3.96% of the Group’s Immatics US, Inc. subsidiary as of June 30, 2020, held by MD Anderson. On July 1, 2020 and as part of the ARYA Merger, this

non-controlling

interest in Immatics US, Inc. was exchanged for ordinary shares in Immatics N.V.

3.2 Restatement of Unaudited Condensed Consolidated Financial Statements to correct the presentation of the warrants

The financial statements of 2020 were restated in the Amendment No. 1 of the 20-F published on October 28, 2021.

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Financial Position as of June 30, 2021:


	As of June 30, 2021
	As previously reported			Adjustment			As restated
	(Euros in thousands)
Total Assets		216,505			—			216,505

Other financial liabilities		—			20,805			20,805

Total current liabilities		73,128			20,805			93,933

Total non-current liabilities		66,937			—			66,937

Total liabilities		140,065			20,805			160,870

Shareholders’ equity (deficit)
Share capital		629			—			629
Share premium		589,609			(34,644	)		554,965
Accumulated deficit		(507,663	)		13,839			(493,824	)
Other reserves		(6,135	)		—			(6,135	)
Total equity (deficit) attributable to shareholders of the parent		76,440			(20,805	)		55,635

Total shareholders’ equity (deficit)		76,440			(20,805	)		55,635

Total liabilities and shareholders’ equity (deficit)		216,505			—			216,505

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Loss for the three-months ended and six-months ended June 30, 2021:


	Three months ended June 30, 2021									Six months ended June 30, 2021
	As previously reported			Adjustment			As restated			As previously reported			Adjustment			As restated
	(Euros in thousands)									(Euros in thousands)
Change in fair value of warrant liabilities		—			(2,722	)		(2,722	)		—			(3,936	)		(3,936	)

Financial result		(416	)		(2,722	)		(3,138	)		1,824			(3,936	)		(2,112	)

Loss before taxes		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Taxes on income		—			—			—			—			—			—

Net loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Attributable to:
Equity holders of the parent		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Non-controlling interest		—			—			—			—			—			—

Net loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)

Net loss per share - basic and diluted		(0,38	)		(0,04	)		(0,42	)		(0,72	)		(0,06	)		(0,78	)
Weighted average shares outstanding - basic and diluted		62,909,095			—			62,909,095			62,908,945			—			62,908,945

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Comprehensive Loss for the three-months ended and six-months ended June 30, 2021:


	Three months ended June 30, 202 1									Six months ended June 30, 202 1
	As previously reported			Adjustment			As restated			As previously reported			Adjustment			As restated
	(Euros in thousands)									(Euros in thousands)
Net Loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Other comprehensive loss
Currency translation differences from foreign operations		(1,401	)		—			(1,401	)		1,324			—			1,324

Total comprehensive loss for the period		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)
Attributable to:
Equity holders of the parent		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)
Non-controlling interest		—			—			—			—			—			—

Total comprehensive loss for the period		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Cash Flows for six-months ended June 30, 2021:


	Six months ended June 30, 2021
	As previously reported			Adjustment			As restated
	(Euros in thousands)
Loss before taxation		(45,410	)		(3,936	)		(49,346	)
Adjustment to reconcile net loss to net cash used in operating activities		18,823			3,936			22,759
Net cash provided by/(used in) operating activities		(36,602	)		—			(36,602	)
Net cash provided by/(used in) investing activities		(10,306	)		—			(10,306	)
Net cash provided by/(used in) financing activities		(1,348	)		—			(1,348	)

Net decrease in cash and cash equivalents		(48,256	)		—			(48,256	)

Cash and cash equivalents at beginning of period		207,530			—			207,530

Effects of exchange rate changes on cash and cash equivalents		819			—			819

Cash and cash equivalents at end of period		160,093			—			160,093

Significant accounting policies (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Summary of reconciliation of our unaudited condensed Consolidated Statement of Financial Position

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Financial Position as of June 30, 2021:


	As of June 30, 2021
	As previously reported			Adjustment			As restated
	(Euros in thousands)
Total Assets		216,505			—			216,505

Other financial liabilities		—			20,805			20,805

Total current liabilities		73,128			20,805			93,933

Total non-current liabilities		66,937			—			66,937

Total liabilities		140,065			20,805			160,870

Shareholders’ equity (deficit)
Share capital		629			—			629
Share premium		589,609			(34,644	)		554,965
Accumulated deficit		(507,663	)		13,839			(493,824	)
Other reserves		(6,135	)		—			(6,135	)
Total equity (deficit) attributable to shareholders of the parent		76,440			(20,805	)		55,635

Total shareholders’ equity (deficit)		76,440			(20,805	)		55,635

Total liabilities and shareholders’ equity (deficit)		216,505			—			216,505

Summary of reconciliation of our unaudited condensed Consolidated Statement of Loss

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Loss for the three-months ended and six-months ended June 30, 2021:


	Three months ended June 30, 2021									Six months ended June 30, 2021
	As previously reported			Adjustment			As restated			As previously reported			Adjustment			As restated
	(Euros in thousands)									(Euros in thousands)
Change in fair value of warrant liabilities		—			(2,722	)		(2,722	)		—			(3,936	)		(3,936	)

Financial result		(416	)		(2,722	)		(3,138	)		1,824			(3,936	)		(2,112	)

Loss before taxes		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Taxes on income		—			—			—			—			—			—

Net loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Attributable to:
Equity holders of the parent		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Non-controlling interest		—			—			—			—			—			—

Net loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)

Net loss per share - basic and diluted		(0,38	)		(0,04	)		(0,42	)		(0,72	)		(0,06	)		(0,78	)
Weighted average shares outstanding - basic and diluted		62,909,095			—			62,909,095			62,908,945			—			62,908,945

Summary of reconciliation of our unaudited condensed Consolidated Statement of Comprehensive Loss

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Comprehensive Loss for the three-months ended and six-months ended June 30, 2021:


	Three months ended June 30, 202 1									Six months ended June 30, 202 1
	As previously reported			Adjustment			As restated			As previously reported			Adjustment			As restated
	(Euros in thousands)									(Euros in thousands)
Net Loss		(23,812	)		(2,722	)		(26,534	)		(45,410	)		(3,936	)		(49,346	)
Other comprehensive loss
Currency translation differences from foreign operations		(1,401	)		—			(1,401	)		1,324			—			1,324

Total comprehensive loss for the period		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)
Attributable to:
Equity holders of the parent		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)
Non-controlling interest		—			—			—			—			—			—

Total comprehensive loss for the period		(25,213	)		(2,722	)		(27,935	)		(44,086	)		(3,936	)		(48,022	)

Summary of reconciliation of our unaudited condensed Consolidated Statement of Cash Flows

The following represents the reconciliation of our unaudited condensed Consolidated Statement of Cash Flows for six-months ended June 30, 2021:


	Six months ended June 30, 2021
	As previously reported			Adjustment			As restated
	(Euros in thousands)
Loss before taxation		(45,410	)		(3,936	)		(49,346	)
Adjustment to reconcile net loss to net cash used in operating activities		18,823			3,936			22,759
Net cash provided by/(used in) operating activities		(36,602	)		—			(36,602	)
Net cash provided by/(used in) investing activities		(10,306	)		—			(10,306	)
Net cash provided by/(used in) financing activities		(1,348	)		—			(1,348	)

Net decrease in cash and cash equivalents		(48,256	)		—			(48,256	)

Cash and cash equivalents at beginning of period		207,530			—			207,530

Effects of exchange rate changes on cash and cash equivalents		819			—			819

Cash and cash equivalents at end of period		160,093			—			160,093

Other current assets (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Summary of Other current assets


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)
Grant receivable		726		875
Prepaid expenses		1,821		2,389
Positive market value forward contract		9		914
Value added tax receivable		1,240		798
Other assets		1,019		787

Other current assets		4,815		5,763

Revenue from collaboration agreements (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Summary of revenue from collaboration agreements explanatory

The Group earned revenue from collaboration agreements from the following collaborators during the three and six months ended June 30, 2021 and 2020:


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
	(Euros in thousands)				(Euros in thousands)


Amgen		260		561		517		2,712
Genmab		2,105		2,501		4,341		4,515
BMS		1,297		3,241		4,590		5,664
GSK		1,527		593		3,144		1,045

Total		5,189		6,896		12,592		13,936

Summary of Deferred revenue related to the collaboration agreements


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)
Current		57,998		46,600
Non-current		62,201		85,475

Total		120,199		132,075

Financial result (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Summary of finance income and costs

Financial income and financial expenses consist of the following:


	Three months ended June 30,						Six months ended June 30,
	2021 (Restated)			2020			2021 (Restated)			2020
	(Euros in thousands)						(Euros in thousands)


Interest income from Other financial assets		38			436			87			755
Foreign currency gains		19			1			3,014			328
Gain on other financial instruments		156			—			—			—

Financial income		213			437			3,101			1,083

Interest expenses		(140	)		(81	)		(245	)		(110	)
Foreign currency losses		(489	)		(2,083	)		(101	)		—
Losses on other financial instruments		—			—			(931	)		—

Financial expenses		(629	)		(2,164	)		(1,277	)		(110	)
Change in fair value of warrant liabilities		(2,722	)		—			(3,936	)		—

Financial result		(3,138	)		(1,727	)		(2,112	)		973

Provisions (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Provisions

Provisions consisted of the following as of June 30, 2021 and December 31, 2020:


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)

Other provision		50		51
Provision for bonuses		1,910		—

Total provisions		1,960		51

Other current liabilities (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Summary of other current liabilities

Other current liabilities consisted of the following as of June 30, 2021 and December 31, 2020.


	As of
	June 30, 2021		December 31, 2020
	(Euros in thousands)

Payroll tax		296		1,185
Accrual for vacation		1,021		525
Accrued bonuses		—		154
Other		125		161

Total		1,442		2,025

Share-based payments (Tables)

6 Months Ended

Jun. 30, 2021

Statements [Line Items]

Summary of Employee Related Share Based Compensation Expense

The Group recognized total employee-related share-based compensation expense, during the three and six months ended June 30, 2021 and 2020 as set out below:


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
	(Euros in thousands)				(Euros in thousands)

Research and development expenses		4,676		4,843		9,574		5,284
General and administrative expenses		3,289		3,848		6,695		4,135

Total share-based compensation		7,965		8,691		16,269		9,419

Matching Stock Options [Member]

Statements [Line Items]

Summary of Employee Share Options

Matching Stock Options outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number
Matching Stock Options outstanding on January 1,		10.00		1,422,556
Matching Stock Options forfeited		10.00		9,254
Matching Stock Options exercised		—		—
Matching Stock Options expired		—		—
Matching Stock Options outstanding on June 30,		10.00		1,413,302
Matching Stock Options vested		10.00		38,702
Weighted average remaining contract life (years)		9.01

Converted Options [Member]

Statements [Line Items]

Summary of Employee Share Options

Converted Options outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number

Converted Options outstanding on January 1,		2.58		594,844
Converted Options forfeited		1.20		16,958
Converted Options exercised		1.25		734
Converted Options expired		1.20		1,637
Converted Options outstanding on June 30,		2.47		575,515
Converted Options vested		2.49		99,211
Weighted average remaining contract life (years)		6.51

Additional Grants Under 2020 Plan [Member]

Statements [Line Items]

Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model

Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options.


	As of March 30, 2021			As of June 17, 2021			As of June 29, 2021
Exercise price in USD	$	11.68		$	12.05		$	11.93
Underlying share price in USD	$	11.68		$	12.05		$	11.93
Volatility		85.77	%		84.67	%		84.53	%
Time period (years)		6.1			6.11			6.10
Risk free rate		1.17	%		1.10	%		1.08	%
Dividend yield		0.00	%		0.00	%		0.00	%

Summary of Employee Share Options

Service Options outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number

Service Options outstanding on January 1,		9.87		1,910,182
Service Options granted in March,		11.68		90,325
Service Options granted in June,		11.99		75,980
Service Options forfeited		10.46		109,110
Service Options exercised		—		—
Service Options expired		—		—
Service Options outstanding on June 30,		10.65		1,967,377
Service Options vested		—		—
Weighted average remaining contract life (years)		9.57

Performance Based Options [Member]

Statements [Line Items]

Summary of Employee Share Options

PSUs outstanding as of June 30, 2021:


	2021
	Weighted average exercise price in USD		Number

PSUs outstanding on January 1,		10.00		3,644,000
PSUs forfeited		10.00		12,000
PSUs outstanding on June 30,		10.00		3,632,000
PSUs vested		—		—
Weighted average remaining contract life (years)		9.11

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2021

Text Block [Abstract]

Summary of Carrying Amounts and Fair values of Group's Financial Instruments

Set out below are the carrying amounts and fair values of the Group’s financial instruments that are carried in the interim condensed consolidated financial statements.


Euros in thousands		Carrying amount				Fair value
	IFRS 9	June 30, 2021 (Restated)		December 31, 2020		June 30, 2021 (Restated)		December 31, 2020

Financial assets
Short-term deposits*	other financial assets at amortized cost		21,037		24,448		21,037		24,448
Bonds*	other financial assets at amortized cost		11,675		—		11,666		—
Positive market value forward contract*	At fair value through profit or loss (FVTPL)		9		914		9		914
Accounts receivable	other financial assets at amortized cost		718		1,250		718		1,250
Other current/non-current assets	other financial assets at amortized cost		578		1,586		578		1,586

Total financial assets**			34,017		28,198		34,008		28,198

Financial liabilities
Accounts payable	other financial liabilities at amortized cost		9,407		10,052		9,407		10,052
Negative market value forward contracts*	At fair value through profit or loss (FVTPL)		40		—		40		—
Other current liabilities	other financial liabilities at amortized cost		1,402		2,025		1,402		2,025
Other financial liabilities	At fair value through profit or loss (FVTPL)		20,805		16,869		20,805		16,869

Total financial liabilities			31,654		28,946		31,654		28,946

*	“Short-term deposits” are classified within Other financial assets. “Bonds” are classified within Other financial assets. “Positive market value forward contract” are classified in Other current assets. “Negative market value forward contracts” are classified in Other current liabilities.

**	Financial assets, other than cash and cash equivalents.

Group information - Additional Information (Detail)		3 Months Ended	6 Months Ended
Group information - Additional Information (Detail)	Aug. 10, 2021	Jun. 30, 2021	Jun. 30, 2021
Disclosure of non-adjusting events after reporting period [line items]
Date of end of reporting period		Jun. 30, 2021	Jun. 30, 2021
Authorization Of Financial Statements [Member]
Disclosure of non-adjusting events after reporting period [line items]
Date of authorisation for issue of financial statements	Aug. 05, 2021

Significant accounting policies - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020
Immatics US Inc [Member]
Disclosure of subsidiaries [line items]
Ownership interests held by non-controlling interests	3.96%

Significant accounting policies - Summary of reconciliation of our unaudited interim Consolidated Balance Sheet (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Condensed Balance Sheet Statements [Line Items]
Total assets	€ 216,505	€ 254,646
Other financial liabilities	20,805	16,869
Total current liabilities	93,933	77,478
Total non-current liabilities	66,937	89,781
Total liabilities	160,870
Shareholders' equity (deficit)
Share capital	629	629
Share premium	554,965	538,695
Accumulated deficit	(493,824)	(444,478)
Other reserves	(6,135)	(7,459)
Total equity (deficit) attributable to shareholders of the parent	55,635
Total shareholders' equity	55,635	87,387	€ (67,991)	€ (40,835)
Total liabilities and shareholders' equity	216,505	€ 254,646
Previously stated [member]
Condensed Balance Sheet Statements [Line Items]
Total assets	216,505
Total current liabilities	73,128
Total non-current liabilities	66,937
Total liabilities	140,065
Shareholders' equity (deficit)
Share capital	629
Share premium	589,609
Accumulated deficit	(507,663)
Other reserves	(6,135)
Total equity (deficit) attributable to shareholders of the parent	76,440
Total shareholders' equity	76,440
Total liabilities and shareholders' equity	216,505
Increase (decrease) due to corrections of prior period errors [member]
Condensed Balance Sheet Statements [Line Items]
Other financial liabilities	20,805
Total current liabilities	20,805
Total liabilities	20,805
Shareholders' equity (deficit)
Share premium	(34,644)
Accumulated deficit	13,839
Total equity (deficit) attributable to shareholders of the parent	(20,805)
Total shareholders' equity	€ (20,805)

Significant accounting policies - Summary of reconciliation of our unaudited interim Consolidated Statement of Loss (Details) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Income Statement [Line Items]
Change in fair value of warrant liabilities	€ 2,722		€ 3,936
Financial result	(3,138)	€ (1,727)	(2,112)	€ 973
Loss before taxes	(26,534)	(21,326)	(49,346)	(29,906)
Net loss	(26,534)	(21,326)	(49,346)	(29,906)
Attributable to:
Equity holders of the parent	(26,534)	(21,043)	(49,346)	(29,349)
Net Loss	€ (26,534)	€ (21,326)	€ (49,346)	€ (29,906)
Net loss per share—basic and diluted	€ (0.42)	€ (0.64)	€ (0.78)	€ (0.89)
Weighted average shares outstanding—basic and diluted	62,909,095	33,093,838	62,908,945	33,093,838
Previously stated [member]
Condensed Income Statement [Line Items]
Financial result	€ (416)		€ 1,824
Loss before taxes	(23,812)		(45,410)
Net loss	(23,812)		(45,410)
Attributable to:
Equity holders of the parent	(23,812)		(45,410)
Net Loss	€ (23,812)		€ (45,410)
Net loss per share—basic and diluted	€ (0.38)		€ (0.72)
Increase (decrease) due to corrections of prior period errors [member]
Condensed Income Statement [Line Items]
Change in fair value of warrant liabilities	€ (2,722)		€ (3,936)
Financial result	(2,722)		(3,936)
Loss before taxes	(2,722)		(3,936)
Net loss	(2,722)		(3,936)
Attributable to:
Equity holders of the parent	(2,722)		(3,936)
Net Loss	€ (2,722)		€ (3,936)
Net loss per share—basic and diluted	€ (0.04)		€ (0.06)

Significant accounting policies - Summary of reconciliation of our unaudited interim Consolidated Statement of Comprehensive Loss (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Statement Of Comprehensive Income [Line Items]
Net Loss	€ (26,534)	€ (21,326)	€ (49,346)	€ (29,906)
Other comprehensive loss
Currency translation differences from foreign operations	(1,401)	791	1,324	99
Total comprehensive loss for the period	(27,935)	(20,535)	(48,022)	(29,807)
Attributable to:
Equity holders of the parent	(27,935)	(20,252)	(48,022)	(29,250)
Total comprehensive loss for the period	(27,935)	€ (20,535)	(48,022)	€ (29,807)
Previously stated [member]
Condensed Statement Of Comprehensive Income [Line Items]
Net Loss	(23,812)		(45,410)
Other comprehensive loss
Currency translation differences from foreign operations	(1,401)		1,324
Total comprehensive loss for the period	(25,213)		(44,086)
Attributable to:
Equity holders of the parent	(25,213)		(44,086)
Total comprehensive loss for the period	(25,213)		(44,086)
Increase (decrease) due to corrections of prior period errors [member]
Condensed Statement Of Comprehensive Income [Line Items]
Net Loss	(2,722)		(3,936)
Other comprehensive loss
Total comprehensive loss for the period	(2,722)		(3,936)
Attributable to:
Equity holders of the parent	(2,722)		(3,936)
Total comprehensive loss for the period	€ (2,722)		€ (3,936)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

Significant accounting policies - Summary of reconciliation of our unaudited interim Consolidated Statement of Cash Flow (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Cash Flow Statement [Line Items]
Loss before taxation	€ (26,534)	€ (21,326)	€ (49,346)	€ (29,906)
Adjustment to reconcile net loss to net cash used in operating activities			22,759
Net cash provided by/ (used in) operating activities			(36,602)	(27,738)
Net cash provided by/ (used in) investing activities			(10,306)	11,472
Net cash provided by/(used in) financing activities			(1,348)	(1,168)
Net decrease in cash and cash equivalents			(48,256)	(17,434)
Cash and cash equivalents at beginning of period			207,530	103,353
Effects of exchange rate changes on cash and cash equivalents			819	137
Cash and cash equivalents at end of period	160,093	€ 86,056	160,093	€ 86,056
Previously stated [member]
Condensed Cash Flow Statement [Line Items]
Loss before taxation	(23,812)		(45,410)
Adjustment to reconcile net loss to net cash used in operating activities			18,823
Net cash provided by/ (used in) operating activities			(36,602)
Net cash provided by/ (used in) investing activities			(10,306)
Net cash provided by/(used in) financing activities			(1,348)
Net decrease in cash and cash equivalents			(48,256)
Cash and cash equivalents at beginning of period			207,530
Effects of exchange rate changes on cash and cash equivalents			819
Cash and cash equivalents at end of period	160,093		160,093
Increase (decrease) due to corrections of prior period errors [member]
Condensed Cash Flow Statement [Line Items]
Loss before taxation	€ (2,722)		(3,936)
Adjustment to reconcile net loss to net cash used in operating activities			€ 3,936

Other current assets -Summary of Other current assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Trade and other receivables [abstract]
Grant receivable	€ 726	€ 875
Prepaid expenses	1,821	2,389
Positive market value forward contract	9	914
Value added tax receivable	1,240	798
Other assets	1,019	787
Other current assets	€ 4,815	€ 5,763

Other current assets - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Other Current Assets [Line Items]
Prepaid insurance expenses	€ 200	€ 1,000
Prepaid expenses of licenses and software	500	600
Other assets	1,019	787
Receivables From Capital Gains Tax [Member]
Disclosure of Other Current Assets [Line Items]
Other assets	400	400
Celgene Switzerland LLC And Genmab AS [Member]
Disclosure of Other Current Assets [Line Items]
Current Incremental cost for collaboration agreement	€ 600	€ 500

Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	€ 5,189	€ 6,896	€ 12,592	€ 13,936
Amgen
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	260	561	517	2,712
Genmab
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	2,105	2,501	4,341	4,515
BMS
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	1,297	3,241	4,590	5,664
GSK
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	€ 1,527	€ 593	€ 3,144	€ 1,045

Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Revenue [abstract]
Current	€ 57,998	€ 46,600
Non-current	62,201	85,475
Total	€ 120,199	€ 132,075

Revenue from collaboration agreements - Additional Information (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Revenue From Contract With Customers [Line Items]
Amortization of contract costs capitalized	€ 50	€ 80	€ 130	€ 150
Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Milestone or royalty payment receivable	€ 0		€ 0

Financial result - Summary of finance income and costs (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Detailed Information About Finance Income Expense [Abstract]
Interest income from Other financial assets	€ 38	€ 436	€ 87	€ 755
Foreign currency gains	19	1	3,014	328
Gain on other financial instruments	156
Financial income	213	437	3,101	1,083
Interest expenses	(140)	(81)	(245)	(110)
Foreign currency losses	(489)	(2,083)	(101)
Losses on other financial instruments			(931)
Financial expenses	(629)	(2,164)	(1,277)	(110)
Change in fair value of warrant liabilities	(2,722)		(3,936)
Financial result	€ (3,138)	€ (1,727)	€ (2,112)	€ 973

Financial result - Additional Information (Details) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Statements [Line Items]
Change in fair value of warrant liabilities	€ 2,722	€ 3,936
Bottom of range [member]
Statements [Line Items]
Exercise Price of Warrants or Rights			€ 2.52	€ 2.35
Top of range [member]
Statements [Line Items]
Exercise Price of Warrants or Rights	€ 2.89	€ 2.89	€ 2.52

Income Tax - Additional Information (Detail) - EUR (€)	3 Months Ended		6 Months Ended
Income Tax - Additional Information (Detail) - EUR (€)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Statements [Line Items]
statutory tax rate	29.10%	29.10%	29.10%	29.10%
corporate income tax rate	21.00%	21.00%	21.00%	21.00%
Deferred Tax Assets Recognized In Respect Of Losses Due To Uncertainty [Member]
Statements [Line Items]
Deferred tax assets	€ 0		€ 0		€ 0

Intangible assets, Property, plant and equipment and Right-of-use assets - Additional Information (Detail) - EUR (€) € in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statements [Line Items]
Purchase of property, plant and equipment	€ 1.8	€ 1.3	€ 2.4	€ 3.0
Right of use assets, future lease payments	0.1		0.1
Rental Land [Member]
Statements [Line Items]
Addition to right-of-use assets			1.8
Rental Land [Member] \| Less than 1year
Statements [Line Items]
Right of use assets, future lease payments	0.3		0.3
Rental Land [Member] \| Later than four years and not later than five years [member]
Statements [Line Items]
Right of use assets, future lease payments	€ 1.5		€ 1.5

Provisions - Summary of Provisions (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Provisions [abstract]
Other provision	€ 50	€ 51
Provision for bonuses	1,910
Total provisions	€ 1,960	€ 51

Other current liabilities - Summary of other current liabilities (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of detailed information about other current liabilities [Line Items]
Payroll tax	€ 296	€ 1,185
Accrual for vacation	1,021	525
Accrued bonuses		154
Other	125	161
Total	€ 1,442	€ 2,025

Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail) - Additional Grants Under 2020 Plan [Member]	Jun. 29, 2021 yr $ / shares	Jun. 17, 2021 yr $ / shares	Mar. 30, 2021 yr $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 11.93	$ 12.05	$ 11.68
Underlying share price	$ 11.93	$ 12.05	$ 11.68
Volatility	84.53%	84.67%	85.77%
Time period (years) \| yr	6.10	6.11	6.1
Risk free rate	1.08%	1.10%	1.17%
Dividend yield	0.00%	0.00%	0.00%

Share-based payments - Summary of Employee Share Options (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2021 shares $ / shares	Jun. 30, 2021 shares $ / shares
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 10.00
SARs forfeited \| $ / shares		10.00
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 10.00	10.00
SARs vested \| $ / shares	$ 0	$ 0
Number of share options, outstanding at January 1,		3,644,000
SARs granted	0	0
SARs forfeited		12,000
Number of share options, outstanding at June 30,	3,632,000	3,632,000
SARs vested	0	0
Weighted average remaining contract life (years)		9 years 1 month 9 days
Additional Grants Under 2020 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 9.87
SARs forfeited \| $ / shares		10.46
SARs exercised \| $ / shares		0
SARs expired \| $ / shares		0
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 10.65	10.65
SARs vested \| $ / shares	$ 0	$ 0
Number of share options, outstanding at January 1,		1,910,182
SARs forfeited		109,110
SARs exercised		0
SARs expired		0
Number of share options, outstanding at June 30,	1,967,377	1,967,377
SARs vested	0	0
Weighted average remaining contract life (years)		9 years 6 months 25 days
Additional Grants Under 2020 Plan [Member] \| Granted On March 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted \| $ / shares		$ 11.68
SARs granted		90,325
Additional Grants Under 2020 Plan [Member] \| Granted On June 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted \| $ / shares		$ 11.99
SARs granted		75,980
Converted Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 2.58
SARs forfeited \| $ / shares		1.20
SARs exercised \| $ / shares		1.25
SARs expired \| $ / shares		1.20
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 2.47	2.47
SARs vested \| $ / shares	$ 2.49	$ 2.49
Number of share options, outstanding at January 1,		594,844
SARs forfeited		16,958
SARs exercised		734
SARs expired		1,637
Number of share options, outstanding at June 30,	575,515	575,515
SARs vested	99,211	99,211
Weighted average remaining contract life (years)		6 years 6 months 3 days
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 10.00
SARs forfeited \| $ / shares		10.00
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 10.00	10.00
SARs vested \| $ / shares	$ 10.00	$ 10.00
Number of share options, outstanding at January 1,		1,422,556
SARs forfeited		9,254
Number of share options, outstanding at June 30,	1,413,302	1,413,302
SARs vested	38,702	38,702
Weighted average remaining contract life (years)		9 years 3 days

Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	€ 7,965	€ 8,691	€ 16,269	€ 9,419
Research And Development Expense [Member]
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	4,676	4,843	9,574	5,284
General And Administrative Expense [Member]
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	€ 3,289	€ 3,848	€ 6,695	€ 4,135

Share-based payments - Additional Information (Detail) $ / shares in Units, € in Thousands, $ in Billions				3 Months Ended		6 Months Ended
	Jun. 29, 2021 $ / shares	Jun. 17, 2021 $ / shares	Mar. 30, 2021 $ / shares	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2020 EUR (€)	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2021 USD ($) $ / shares	Jun. 30, 2020 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €				€ 7,965	€ 8,691	€ 16,269		€ 9,419
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted \| shares				0		0
Performance Based Options [Member] \| Tranche One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $							$ 1.5
Performance Based Options [Member] \| Tranche Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $							2.0
Performance Based Options [Member] \| Tranche Three [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $							$ 3.0
Additional Grants Under 2020 Plan [Member] \| Granted On March 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted \| shares						90,325
Share based compensation by share based payment arrangement exercise price per share granted							$ 11.68
Share based compensation by share based payment arrangement fair value per share			$ 8.48
Additional Grants Under 2020 Plan [Member] \| Granted On June 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted \| shares						75,980
Share based compensation by share based payment arrangement exercise price per share granted							11.99
Share based compensation by share based payment arrangement fair value per share	$ 8.48	$ 8.48
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement exercise price per share granted							$ 10
Share based compensation by share based payment arrangement term of stock options						ten-year
Date of vesting of stock options						Jul. 31, 2021
2010 and 2016 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €								800
2010 and 2016 Plan \| Cash Settled Award [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €								700
2010 and 2016 Plan \| Equity Settled Award [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €								€ 100

Related party disclosures - Additional Information (Detail) - shares		6 Months Ended
	Jun. 17, 2021	Jun. 30, 2021
Disclosure of transactions between related parties [line items]
Description of Transactions with related party		During the three and six months ended June 30, 2021 the Group did not enter into any new related-party transactions with its key management personnel or with related entities other than renewed service contracts for members of the Supervisory Board based on their election at the Annual General Meeting held on June 17, 2021. As part of his election, Dr. Friedrich von Bohlen und Halbach has been granted 25,000 Service Options.
Dr. Friedrich Von Bohlen Und Halbach [Member]
Disclosure of transactions between related parties [line items]
Related party transaction, Options granted	25,000

Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	€ 34,017	€ 28,198
Financial liabilities, Carrying amount	31,654	28,946
Financial assets, Fair value	34,008	28,198
Financial liabilities, Fair value	31,654	28,946
Financial assets at fair value through profit or loss, category [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	20,805	16,869
Financial liabilities, Fair value	20,805	16,869
Financial assets at fair value through profit or loss, category [member] \| Positive Market Value Forward Contracts [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	9	914
Financial assets, Fair value	9	914
Financial assets at fair value through profit or loss, category [member] \| Negative Market Value Forward Contracts [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	40	0
Financial liabilities, Fair value	40	0
Other Financial Assets At Amortized Cost [Member] \| ShortTerm Deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	21,037	24,448
Financial assets, Fair value	21,037	24,448
Other Financial Assets At Amortized Cost [Member] \| Bonds [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	11,675	0
Financial assets, Fair value	11,666	0
Other Financial Assets At Amortized Cost [Member] \| Trade receivables [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	718	1,250
Financial assets, Fair value	718	1,250
Other Financial Assets At Amortized Cost [Member] \| Other current/non-current assets [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	578	1,586
Financial assets, Fair value	578	1,586
Other Financial Assets At Amortized Cost [Member] \| Accounts Payable [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	9,407	10,052
Financial liabilities, Fair value	9,407	10,052
Other Financial Assets At Amortized Cost [Member] \| Other Current Liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	1,402	2,025
Financial liabilities, Fair value	€ 1,402	€ 2,025